Rain Therapeutics to Present Data on Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting 2019

NEWARK,
Calif., February 28, 2019 — Rain Therapeutics Inc., a privately-held, clinical
stage biotechnology company focused on biomarker-driven, small molecule therapeutics
for patients with cancer, today announced presentations of preclinical data from
ongoing studies of Rain’s lead candidate, tarloxotinib, at the American Association
for Cancer Research (AACR) Annual Meeting 2019 being held March 29-April 3,
2019 in Atlanta, Georgia. Poster presentations will feature data detailing in vitro activity of tarloxotinib for a
variety of EGFR/ HER2 mutations and in
vitro and in vivo efficacy in
NRG1 altered cancers, as well as data demonstrating that STEAP4 expression can
serve as an additional biomarker to predict sensitivity to tarloxotinib therapy
in upcoming clinical trials.

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain Therapeutics website after the presentations conclude.

About Rain Therapeutics Inc.

Rain
Therapeutics Inc. is a privately-held biotechnology company developing
biomarker-driven small molecule therapeutics for patients with cancer. Rain’s
lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB
inhibitor in development as a treatment for non-small cell lung cancer patients
with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has
worldwide development and commercialization rights for Tarloxotinib. For more
information, visit www.rainthera.com